Patient and disease characteristics by treatment type
| . | Overall (N = 221) . | Intensive induction chemotherapy∗ (n = 147) . | HMA/VEN (n = 74) . | P value . |
|---|---|---|---|---|
| Sex (male) | 100 (45%) | 72 (49%) | 28 (38%) | .15 |
| Age at diagnosis (median, range) | 68.6 (60-89) | 65.9 (60-79) | 74.9 (63-89) | <.001 |
| Age at diagnosis (% within age group) | <.001 | |||
| 60-75 y | 178 (81%) | 137 (93%) | 41 (55%) | |
| >75 y | 43 (19%) | 10 (6.8%) | 33 (45%) | |
| Prior MDS, MPN, or MDS/MPN | 21 (9.5%) | 8 (5.4%) | 13 (18%) | .006 |
| Prior HMA therapy for MDS, MPN or MDS/MPN | 7 (3.2%) | 4 (2.7%) | 3 (4.1%) | .69 |
| Therapy-related disease† | 28 (13%) | 16 (11%) | 12 (16%) | .29 |
| Cytogenetics‡ | ||||
| Normal | 179 (86%) | 126 (90%) | 53 (77%) | .02 |
| Monosomal | 1 (0.5%) | 1 (0.7%) | 0 | >.99 |
| Complex | 3 (1.4%) | 3 (2.2%) | 0 | .55 |
| Molecular§ | ||||
| CEBPA | 17 (8.4%) | 11 (8.5%) | 6 (8.1%) | >.99 |
| DNMT3A | 89 (44%) | 58 (45%) | 31 (42%) | .77 |
| FLT3-ITD | 80 (36%) | 58 (39%) | 22 (30%) | .18 |
| FLT3-TKD | 37 (17%) | 26 (18%) | 11 (15%) | .70 |
| IDH1 | 32 (14%) | 22 (15%) | 10 (14%) | .84 |
| IDH2 | 50 (23%) | 29 (20%) | 21 (28%) | .17 |
| NRAS | 24 (12%) | 17 (13%) | 7 (9.5%) | .50 |
| PTPN11 | 30 (16%) | 18 (15%) | 12 (16%) | .84 |
| SF3B1 | 17 (8.4%) | 6 (4.7%) | 11 (15%) | .017 |
| SRSF2 | 27 (14%) | 11 (9.2%) | 16 (22%) | .019 |
| TET2 | 70 (34%) | 42 (33%) | 28 (38%) | .45 |
| WT1 | 13 (6.4%) | 9 (7.0%) | 4 (5.5%) | .77 |
| . | Overall (N = 221) . | Intensive induction chemotherapy∗ (n = 147) . | HMA/VEN (n = 74) . | P value . |
|---|---|---|---|---|
| Sex (male) | 100 (45%) | 72 (49%) | 28 (38%) | .15 |
| Age at diagnosis (median, range) | 68.6 (60-89) | 65.9 (60-79) | 74.9 (63-89) | <.001 |
| Age at diagnosis (% within age group) | <.001 | |||
| 60-75 y | 178 (81%) | 137 (93%) | 41 (55%) | |
| >75 y | 43 (19%) | 10 (6.8%) | 33 (45%) | |
| Prior MDS, MPN, or MDS/MPN | 21 (9.5%) | 8 (5.4%) | 13 (18%) | .006 |
| Prior HMA therapy for MDS, MPN or MDS/MPN | 7 (3.2%) | 4 (2.7%) | 3 (4.1%) | .69 |
| Therapy-related disease† | 28 (13%) | 16 (11%) | 12 (16%) | .29 |
| Cytogenetics‡ | ||||
| Normal | 179 (86%) | 126 (90%) | 53 (77%) | .02 |
| Monosomal | 1 (0.5%) | 1 (0.7%) | 0 | >.99 |
| Complex | 3 (1.4%) | 3 (2.2%) | 0 | .55 |
| Molecular§ | ||||
| CEBPA | 17 (8.4%) | 11 (8.5%) | 6 (8.1%) | >.99 |
| DNMT3A | 89 (44%) | 58 (45%) | 31 (42%) | .77 |
| FLT3-ITD | 80 (36%) | 58 (39%) | 22 (30%) | .18 |
| FLT3-TKD | 37 (17%) | 26 (18%) | 11 (15%) | .70 |
| IDH1 | 32 (14%) | 22 (15%) | 10 (14%) | .84 |
| IDH2 | 50 (23%) | 29 (20%) | 21 (28%) | .17 |
| NRAS | 24 (12%) | 17 (13%) | 7 (9.5%) | .50 |
| PTPN11 | 30 (16%) | 18 (15%) | 12 (16%) | .84 |
| SF3B1 | 17 (8.4%) | 6 (4.7%) | 11 (15%) | .017 |
| SRSF2 | 27 (14%) | 11 (9.2%) | 16 (22%) | .019 |
| TET2 | 70 (34%) | 42 (33%) | 28 (38%) | .45 |
| WT1 | 13 (6.4%) | 9 (7.0%) | 4 (5.5%) | .77 |
TKD, tyrosine kinase domain.
Composite of 7 + 3 and liposomal cytarabine/daunorubicin.
Therapy-related disease was defined as receipt of chemotherapy and/or radiation for a prior nonmyeloid neoplasm.
Cytogenetic analysis was available in 209 of 221 patients (95%) .
Only mutations present in ≥5% of patients included.